Posted by Michael Wonder on 12 Feb 2024
FDA accepts Xspray Pharma’s NDA resubmission for Dasynoc
12 February 2024 - The US FDA has accepted the resubmission of Xspray Pharma’s new drug application for Dasynoc, following a complete response letter where additional information was requested.
The FDA has now assigned a Prescription Drug User Fee Act date to 31July 2024.
